^
Association details:
| Biomarker: | AKT1 E17K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Excerpt:
Confirmed partial responses (PR) in RECIST criteria were experienced by two patients, both receiving intermittent AZD5363 dosing (480 mg 4 days on/3 days off and 640 mg 2 days on/5 days off). Tumor samples from these two responders were subjected to mutation profiling by next-generation sequencing and each was found to have AKT1E17K mutation in archival primary tumor.
DOI:
10.1158/1535-7163.MCT-15-0230
Trial ID:
Test:
